Gilead Analyst: Coronavirus Drug, Arcus Collaboration Make Biopharma A Buy
The consensus estimates for Gilead Sciences, Inc. (NASDAQ: GILD) appear overly conservative, especially given the prospects of remdesivir and products from the company’s recent collaboration with Arcus Biosciences Inc (NYSE: RCUS), according to Leerink.
The Gilead Sciences Analyst
Geoffrey Porges upgraded Gilead Sciences from Market Perform to Outperform and raised the price target from $85 to $94.
The Gilead Sciences Thesis
Remdesivir is likely to be sold for both commercial use and government stockpiles, reaching a revenue peak of $7.7 billion in 2022, Porges said in the Wednesday upgrade note.
Stockpile sales could begin by late 2021, the analyst said, adding that he expects the commercial price of remdesivir to be $5,000 per course in the U.S., $4,000 in Europe and $2,000 in other markets.
Although there is a great deal of uncertainty around the revenue and profit contribution from remdesivir, Gilead Sciences has other opportunities from the successful development of its expanded pipeline, Porges said.
The recently announced deal with Arcus Biosciences provides Gilead with “critical mass in oncology with a diverse and synergistic pipeline, and boosts our confidence for investing in the stock long term,” the analyst said.
Leerink raised its earnings estimates for 2020 and 2021 from $6.66 per share to $6.80 per share and from $7.01 per share to $7.74 per share, respectively.
GILD Price Action
Shares of Gilead Sciences were up 1.04% at $74.02 at the time of publication Wednesday.
Related Links:
Gilead Falls On Mixed Results From Late-Stage Remdesivir Study In Moderate COVID-19
The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer
Latest Ratings for GILD
May 2020 | SunTrust Robinson Humphrey | Upgrades | Sell | Hold |
May 2020 | SVB Leerink | Maintains | Market Perform | |
May 2020 | Oppenheimer | Maintains | Outperform |
View More Analyst Ratings for GILD
View the Latest Analyst Ratings
See more from Benzinga
Slack Has Big Tailwind Amid Work-From-Home Shift, Cowen Says
BofA Downgraded AerCap On Heightened Risk Related To Residual Values
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
